TRC-EID

E-BOOK

Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19
Background document to the WHO Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing
BY :
TRC Admin
Views :
612
TYPE :
pdf
DOWNLOAD
  • 918
  • 1298
  • 25
  • 1
  • 0.06
  • true
  • false
  • true
  • true
  • false
  • true
  • false
  • https://trceid.org//upload/ebo/file/file-20211601-1610761057-585-Thai-914.pdf
  • 1
  • double
TRC-EID

RELATED E-BOOK

COVID-19 laboratory biosafety: elaborations on the latest WHO Laboratory biosafety guidance related to COVID-19 EURO Webinar, 12 November 2020

COVID-19 laboratory biosafety: elaborations on the latest WHO Laboratory biosafety guidance related to COVID-19 EURO Webinar, 12 November 2020
ENG BSC safe practices

ENG BSC safe practices
สู้! โควิด-19 ไปด้วยกัน คู่มือดูแลตัวเองสำหรับประชาชน

สู้! โควิด-19 ไปด้วยกัน คู่มือดูแลตัวเองสำหรับประชาชน
Thai Bat Book Small

Thai Bat Book Small
Virtual workshop on Biological Safety Cabinet (BSC) performance checking ENG

Virtual workshop on Biological Safety Cabinet (BSC) performance checking ENG
Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health
Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing
Analysing and using routine data to monitor the effects of COVID-19 on essential health services

Analysing and using routine data to monitor the effects of COVID-19 on essential health services
Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19

Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19
Weekly epidemiological update - 19 January 2021

Weekly epidemiological update - 19 January 2021
Evaluation of implementation of Regional Flagship Areas in the WHO South-East Asia Region 2014–2018

Evaluation of implementation of Regional Flagship Areas in the WHO South-East Asia Region 2014–2018
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Neurology Neuroradiology X-ray conference

Neurology Neuroradiology X-ray conference
CNS Infection

CNS Infection
CNS Infection II

CNS Infection II
Practical considerations and recommendations for religious leaders and faith-based communities in the context of COVID-19

Practical considerations and recommendations for religious leaders and faith-based communities in the context of COVID-19
CLICK TO VERIFY: This site uses a GlobalSign SSL Certificate to secure your personal information.